文献速递临床试验与 GCP基础与转化研究

抗CD19 CAR T细胞疗法治疗难治性系统性红斑狼疮

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
PubMed 文献 · Nat Med · 2022-09-15

5例难治性系统性红斑狼疮(SLE)患者入组同情用药CD19 CAR T细胞项目,经氟达拉滨和环磷酰胺清淋后回输1×10^6 CAR T细胞/kg。CAR T细胞体内扩增导致B细胞深度耗竭,全部5例在3个月时达到DORIS缓解标准,中位随访8个月无药缓解维持。

要点

  • 抗CD19 CAR T细胞治疗后全部5例SLE患者在3个月时达到DORIS缓解标准。
  • 治疗3个月后中位SLE疾病活动指数评分为0(范围2)。
  • 治疗耐受良好,仅出现轻度细胞因子释放综合征。

核心结论

  • CD19 CAR T细胞输注在SLE中可行、可耐受且高度有效。

研究设计与样本

  • 同情用药CAR T细胞项目,纳入5例SLE患者(4女1男),中位(范围)年龄22(6)岁,中位(范围)病程4(8)年,中位(范围)SLE疾病活动指数16(8),对多种免疫抑制药物治疗难治。
  • 自体T细胞经慢病毒抗CD19 CAR载体转导、扩增,在氟达拉滨和环磷酰胺清淋后以1×10^6 CAR T细胞/kg体重回输。

主要发现

  • CAR T细胞体内扩增,导致B细胞深度耗竭,临床症状改善,实验室指标正常化,包括抗双链DNA抗体血清学转换。
  • 全部5例患者在3个月时达到DORIS标准SLE缓解,3个月后中位(范围)SLE疾病活动指数评分为0(2)。
  • 在较长随访期间(CAR T细胞给药后中位(范围)8(12)个月)无药缓解维持,甚至在B细胞重新出现后仍维持。
  • B细胞重新出现于CAR T细胞治疗后平均(±s.d.)110±32天,重现的B细胞为初始B细胞,显示非类别转换的B细胞受体。
  • CAR T细胞治疗耐受良好,仅出现轻度细胞因子释放综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized by adaptive immune system activation, formation of double-stranded DNA autoantibodies and organ inflammation. Five patients with SLE (four women and one man) with a median (range) age of 22 (6) years, median (range) disease duration of 4 (8) years and active disease (median (range) SLE disease activity index Systemic Lupus Erythematosus Disease Activity Index: 16 (8)) refractory to several immunosuppressive drug treatments were enrolled in a compassionate-use chimeric antigen receptor (CAR) T cell program. Autologous T cells from patients with SLE were transduced with a lentiviral anti-CD19 CAR vector, expanded and reinfused at a dose of 1 × 106 CAR T cells per kg body weight into the patients after lymphodepletion with fludarabine and cyclophosphamide. CAR T cells expanded in vivo, led to deep depletion of B cells, improvement of clinical symptoms and normalization of laboratory parameters including seroconversion of anti-double-stranded DNA antibodies. Remission of SLE according to DORIS criteria was achieved in all five patients after 3 months and the median (range) Systemic Lupus Erythematosus Disease Activity Index score after 3 months was 0 (2). Drug-free remission was maintained during longer follow-up (median (range) of 8 (12) months after CAR T cell administration) and even after the reappearance of B cells, which was observed after a mean (±s.d.) of 110 ± 32 d after CAR T cell treatment. Reappearing B cells were naïve and showed non-class-switched B cell receptors. CAR T cell treatment was well tolerated with only mild cytokine-release syndrome. These data suggest that CD19 CAR T cell transfer is feasible, tolerable and highly effective in SLE.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022. PMID: 36109639. doi:10.1038/s41591-022-02017-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。